US Stock MarketDetailed Quotes
CNTX Context Therapeutics
- 2.2200
- +0.1000+4.72%
Close Jul 22 16:00 ET
- 2.1300
- -0.0900-4.05%
Post 18:27 ET
166.50MMarket Cap-1669P/E (TTM)
2.2200High2.0925Low73.89KVolume2.0925Open2.1200Pre Close161.84KTurnover0.17%Turnover RatioLossP/E (Static)75.00MShares2.240052wk High19.65P/B97.41MFloat Cap0.770052wk Low--Dividend TTM43.88MShs Float10.8700Historical High--Div YieldTTM6.01%Amplitude0.4700Historical Low2.1900Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Context Therapeutics Stock Forum
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
Context Therapeutics, a biopharmaceutical company specializing in solid tumor treatments, has acquired CT-95, a potentially first-in-class mesothelin x CD3 bispecific antibody from Link Immunotherapeutics. This acquisition, announced on July 10, 2024, aligns with Context’s strategy to expand its pipeline of T cell engager assets. CT-95 has already received Investigational New Drug (IND) clearance...
Context Therapeutics Inc. (Nasdaq: CNTX), a Philadelphia-based biopharmaceutical company dedicated to the advancement of treatments for solid tumors, has announced a substantial boost to its financial resources through a private placement aimed at raising approximately $100 million. This strategic financial maneuver is not just about bolstering the company's coffers but is a t...
No comment yet